Welcome to our dedicated page for Utime SEC filings (Ticker: WTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UTime Limited (Nasdaq: WTO) SEC filings page collects the company’s regulatory disclosures, primarily furnished on Form 6-K as a foreign private issuer. These documents explain how UTime describes its business as a consumer electronics and mobile communications company focused on the design, development, manufacture, production, sales and brand operation of mobile devices and smart wearable devices, along with OEM/ODM and Electronics Manufacturing Services for other brands. Through these filings, investors can review official information on product launches, capital raising, governance changes and listing compliance.
UTime’s recent Form 6-K reports include press releases about the launch of a smartwatch with integrated blood pressure monitoring, the release of a smart ring for sleep and continuous health monitoring, and the promotion of smart wearable devices to more international markets. Other 6-Ks cover a Memorandum of Understanding with Hainan Fuxinyi Investment Co., Ltd. to co-develop a digital eldercare services platform, and a procurement agreement for smart health devices through its Hong Kong subsidiary with Tumu Vertex LLC. Filings also describe UTime’s exploration of AI-based health data analysis models using continuous physiological data from its wearables.
From a capital markets perspective, UTime has filed 6-Ks detailing a $25 million best-efforts public offering of units consisting of Class A ordinary shares and warrants, as well as a registered direct offering under a shelf registration statement on Form F-3. Additional filings discuss a private placement used to address Nasdaq’s stockholders’ equity requirement and the company’s plan for a 1-for-100 reverse stock split to support compliance with Nasdaq’s minimum bid price rule.
Corporate governance and structural changes are also documented in these filings, including board resignations and new director appointments, the resignation of the Chief Operating Officer, and the discontinuation and divestiture of certain subsidiaries. By reviewing UTime’s SEC filings alongside AI-powered summaries, readers can quickly identify key topics such as financing terms, listing status, business focus in mobile devices and health wearables, and the company’s approach to eldercare and health data initiatives.
UTime Limited completed a best-efforts registered direct offering raising approximately $1.2 million in gross proceeds. The company sold 200,000 Class A ordinary shares at $1.20 each and issued pre-funded warrants for 800,000 Class A ordinary shares at $0.70 each, with a $0.50 exercise price.
The pre-funded warrants are exercisable immediately until fully exercised and include customary beneficial ownership limits and anti-dilution adjustments. UTime will pay Univest Securities, LLC a 6.0% cash fee on aggregate gross proceeds plus up to $20,000 of expenses. The company plans to use net proceeds for working capital and general corporate purposes, while agreeing to a 30-day issuance standstill and 90-day lock-ups for officers and directors.
UTime Limited is offering 200,000 Class A Ordinary Shares and pre-funded warrants to purchase up to 800,000 Class A Ordinary Shares in a registered direct offering pursuant to a Purchase Agreement dated May 1, 2026. The Class A Ordinary Shares are priced at $1.20 per share and each Pre-Funded Warrant at $0.70, with a $0.50 exercise price per warrant. The prospectus supplement states expected gross proceeds of $1.2 million and estimated net proceeds after fees and expenses of approximately $1.07–1.13 million depending on the table cited. Proceeds are intended for working capital and general corporate purposes; the offering includes customary lock-ups, a placement agent fee of 6.0%, and a 30- to 90-day standstill/lock-up period for the company and insiders.
On April 29, 2026, UTime Limited entered into restricted stock unit grant agreements with each of its five directors. Under these agreements, the Company granted each director 200,000 restricted stock units (RSUs), with each RSU representing one Class A ordinary share.
The RSUs vest immediately upon issuance, meaning the directors gain the associated share rights right away. The form of the grant agreement matches a previously filed template on Form S-8, which the Company incorporates by reference for these grants.
UTime Limited has adopted a new 2026 Equity Incentive Plan to grant equity-based awards to employees, officers, non-employee directors, consultants, independent contractors and advisers. The plan permits issuance of up to 5,000,000 Ordinary Shares as incentives, replacing a prior plan adopted in 2024.
The plan governs options, stock appreciation rights, restricted stock, restricted stock units, stock bonus awards and performance-based compensation. It generally uses three-year vesting, caps option and SAR terms at ten years, and is administered by the board or its compensation committee, with detailed rules for change in control, tax, and legal compliance.
UTime Ltd executive Cao Honggang, who serves as Chief Manufacturing Officer, has filed an initial Form 3 statement of beneficial ownership. The filing does not report any equity transactions or derivative positions and shows no transactional activity by the reporting person at this time.
UTime Ltd director Wang Yanzhi has filed an initial Form 3 statement as a reporting person of the company. The Form 3 is an initial disclosure of beneficial ownership for insiders and, in this case, does not report any insider share transactions or derivative positions.
UTime Ltd director Bao Minfei has filed an initial insider ownership statement showing direct holdings of 36 ordinary shares of the company. This filing does not report any recent purchases or sales; it simply establishes Bao’s current share position as a company insider.
UTime Limited reports unaudited results for the six months ended September 30, 2025, showing a net profit of RMB9.4 million (US$1.3 million) versus a prior-period loss. Revenue declined from RMB138.4 million to RMB99.5 million, but gross profit remained broadly stable at RMB5.5 million.
Liquidity strengthened sharply: cash and cash equivalents rose to RMB293.3 million (US$41.2 million) and working capital improved to RMB7.2 million (current assets RMB399.0 million, current liabilities RMB391.8 million). This was driven mainly by issuance of ordinary shares with subscription proceeds of about RMB338 million, of which RMB160.5 million remains as subscription receivable.
Accumulated deficit was RMB869.6 million (US$122.1 million), total liabilities RMB400.1 million and total shareholders’ equity RMB39.7 million (US$5.6 million). Management cites positive operating cash flow and expected collection of subscription receivables to support preparation of the financial statements on a going concern basis, while highlighting ongoing VIE-related regulatory risks in China.
UTime Limited plans to acquire 100% of Feixiaohao Technology Inc., operator of the “Feixiaohao” Web3 data analytics and asset pricing platform, in a proposed deal valued at up to USD80 million. Consideration would include USD64 million in UTime ordinary or convertible preferred shares and USD16 million in cash.
The companies have signed a non-binding letter of intent and begun preliminary discussions toward a definitive agreement. If completed, the acquisition would add Feixiaohao’s blockchain data infrastructure, user base, technology platforms, trademarks, and key employee contracts to UTime, supporting its push into Web3 services that connect mobile hardware with digital assets.